ALGS — Aligos Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1799448 ·
Last close
$4.23
Market Cap
$22.79M
52W High
$7.08
52W Low
$3.98
ADV30
228,301
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 2,830,000 | — | -26,929,000 | -23,040,000 | 64,558,000 | 29,980,000 | 32,769,000 |
| Dec 2025 | 169,000 | — | -21,814,000 | -19,881,000 | 88,533,000 | 18,303,000 | 34,988,000 |
| Sep 2025 | 741,000 | — | -28,361,000 | -31,537,000 | 109,764,000 | 41,946,000 | 37,931,000 |
| Jun 2025 | 965,000 | — | -18,567,000 | -15,863,000 | 134,706,000 | 18,661,000 | 32,840,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-82,503,000
Investing CF
$-37,826,000
Financing CF
$101,635,000
CapEx
$-437,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.59
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-642,201,000
Inventory
—
Receivables
—
ST Investments
$59,541,000
EBIT TTM
$-87,985,000
Pretax Income TTM
$-23,879,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,705,000
EBITDA
$-94,589,000
Free Cash Flow
$-48,985,376
Enterprise Value
$-23,822,876
Total Cash
$54,909,000
Total Debt
$4,353,000
Shares Out
5,388,223
Trailing EPS
$-9.78
Book Value
$5.14
ROE
-121.9%
ROA
-55.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,186,000 | -87,985,000 | -24,193,000 | 88,533,000 | 34,988,000 | — | -82,503,000 |
| Dec 2024 | 3,945,000 | -89,154,000 | -131,211,000 | 70,094,000 | 99,067,000 | — | -80,743,000 |
| Dec 2023 | 15,529,000 | -88,127,000 | -87,679,000 | 151,527,000 | 59,447,000 | — | -78,997,000 |
| Dec 2022 | 13,907,000 | -97,580,000 | -96,046,000 | 146,693,000 | 42,793,000 | — | -79,389,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.99
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QNCX | Quince Therapeutics, Inc. | $22.87M | $23.39 | — |
| EVAX | Evaxion A/S | $23.52M | $2.82 | — |
| JSPR | Jasper Therapeutics, Inc. | $20.96M | $0.63 | — |
| CVM | CEL SCI CORP | $20.27M | $1.16 | — |
| GRML | Greenland Mines Ltd | $29.17M | $0.19 | — |
News headlines (Yahoo Finance, 1h cache)
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
2026-07-30 12:00 · Yahoo
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
2026-07-13 12:00 · Yahoo
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal
2026-07-06 23:50 · Yahoo
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
2026-07-06 20:05 · Yahoo
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
2026-05-13 06:05 · Yahoo
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
2026-05-07 20:05 · Yahoo
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
2026-04-30 20:05 · Yahoo
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-24 12:00 · Yahoo
Aligos and Xiamen Amoytop sign deal for HBV therapy
2026-04-17 10:54 · Yahoo
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
2026-04-16 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.